S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 11 of the 22 sources its claims cite were checked for support.
Abstract
Significance: Recent exome sequencing studies have uncovered high-frequency histone H3 driver mutations in pediatric cancers. Previous studies have shown that lysine to methionine histone mutations are potent inhibitors of their respective lysine methyltransferases. However, an in-depth understanding of this inhibition was limited by the lack of structural and kinetic information. This study investigates the biochemical and biophysical parameters of lysine to methionine histone mutants using the methyltransferase G9a and H3K9M as a model system. Structural and functional experiments conclude that the methyltransferase cofactor S -adenosyl methionine is required for binding of G9a to the mutant histone.
Overview
CoChat Summary
TL;DR
The histone H3K9M oncohistone inhibits the H3K9 methyltransferase G9a by occupying its active site, but stable G9a–H3K9M interaction requires the cofactor S-adenosyl methionine (SAM). The data support a model in which SAM-bound SET domain methyltransferases are sequestered by K-to-M oncohistones, causing global loss of histone methylation.
Key findings
- H3K9M and K9I transgenes reduced cellular H3K9me2/3, whereas K9A, K9L, and K9R showed little or no reduction; ectopically expressed histones made up less than 5% of total histone H3, indicating a dominant-negative effect.
- Cocrystal structures showed the K9M residue occupies the G9a active site and adopts a conformation virtually identical to the dimethyl-lysine product peptide; SAM was fully occupied in the cofactor pocket even without added SAM, and excess SAH did not displace it.
- SAM is necessary for stable G9a–K9M/Nle binding: G9a bound SAM with a Kd of 2.6 μM, did not bind K9Nle after dialysis, but bound K9Nle with a Kd of 0.032 μM when 1 mM SAM was added; SAH did not promote binding.
- Kinetics with K9Nle showed competitive inhibition with respect to H3 peptide (Kis = 1.6 ± 0.2 nM) and uncompetitive inhibition with respect to SAM (Kii = 66 ± 5 nM).
Methods
- X-ray cocrystallization of G9a-SET with H3K9M, H3K9Nle, and H3K9A peptides; diffraction data collected at Argonne Advanced Photon Source and Canadian Light Source; structures solved by molecular replacement using apo-G9a (PDB 2O8J), with the H3K9M complex at 1.85-Å resolution.
- In vitro histone methyltransferase assays using H3 1-20 peptide (23 μM), 25 nM G9a-SET, and 50 μM SAM; additional binding and kinetic analyses by differential scanning fluorimetry, isothermal titration calorimetry, peptide pulldown, and Michaelis-Menten/Lineweaver-Burk kinetics.
- Cellular assays in lentivirus-transduced 293T/293 cells expressing H3.3 WT or K9X transgenes, with immunoblot analysis of whole-cell extracts and affinity-purified heterotypic mononucleosomes.
Limitations
- The paper does not include a dedicated limitations section.
- Evident from the text: the study uses G9a as a model system, so conclusions about other SET domain methyltransferases and PRC2 are extrapolations.
- Kinetic assays used K9Nle rather than K9M because methionine oxidation decreases potency, and ITC analysis of K9 substrate was complicated by turnover at high substrate/enzyme concentrations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 3 Not checked · 48 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“We and others previously showed that K-to-M oncohistones transform the histone H3 proteins into potent inhibitors of specific lysine methyltransferase enzymes (4-7).”
What the sources say
- Not checked — no full text of the sourcecites [4] matched to “Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas” (2013) source
- Supportedcites [5] matched to “Strategy for “Detoxification” of a Cancer-Derived Histone Mutant Based on Mapping Its Interaction with the Methyltransferase PRC2” (2014) source
The Abstract identifies cancer-associated H3K27M as an inhibitor of the histone methyltransferase PRC2. The experimental passage on H3K27M mononucleosomes (labeled Abstract in our copy; no page given) reports potent inhibition, with KI = 2.1 ± 0.9 nM. This supports the cited sentence through the H3K27M–PRC2 example. (LLM, conf=0.91)
- Supportedcites [6] matched to “Targeted Histone Peptides: Insights into the Spatial Regulation of the Methyltransferase PRC2 by using a Surrogate of Heterotypic Chromatin” (2015) source
The passage labeled Abstract states that the cancer-associated H3K27M mutation creates a potent orthosteric inhibitor of PRC2, a histone lysine methyltransferase. This supports the cited sentence through a specific K-to-M oncohistone example. (LLM, conf=0.88)
- Supportedcites [7] matched to “Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma” (2013) source
The paper’s summary states that K-to-M mutations target the active sites of diverse SET-domain methyltransferases and inhibit their activity. The Abstract also reports that H3K27M inhibits PRC2 and that H3K9M and H3K36M cause specific reductions in methylation through SET-domain enzyme inhibition. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“we previously showed that H3K9M peptides are capable of inhibiting activity of SUV39H1 and G9a, two H3K9-directed methyltransferases, in vitro (7).”
What the sources say
- Supportedcites [7] matched to “Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma” (2013) source
The passage containing Fig. 4H (indexed under Abstract; page not supplied) states that H3K9M peptides inhibit recombinant SUV39H1 and G9a, both H3K9 methyltransferases. It reports inhibitory concentrations for each enzyme, supporting the claim about in vitro activity. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although G9a bound SAM alone with a K d of 2.6 μM (Fig. 3B, Left), G9a did not bind K9Nle peptide after dialysis (Fig. 3B, Center).”
§ S-adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Indeed, purified heterotypic mononucleosomes (containing both H3.2-FLAG-HA and endogenous H3) from cells expressing H3.3 K9M displayed a marked decrease in H3K9me2/3 (Fig. 1 C and D).”
§ S-adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Strikingly, despite an overall similarity in the conformation of peptide and surrounding residues, the crystallized G9a-K9M complex exhibited complete occupancy of SAM within the cofactor binding pocket.”
§ S-adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
31 more claims
Create a free account to see all 59 claims and to verify the 3 references still open.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 17
Citations
Cites
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631 · cited 1×
“Approximately 80% of diffuse intrinsic pontine glioma contain a lysine 27-methionine (K27M) mutation (1, 2), and 95% of chondroblastoma samples contain a K36M mutation in genes encoding either histone H3.”
BackgroundSt. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345 · cited 17×
“Brown ZZ, et al. (2014) Strategy for “detoxification” of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2.”
BackgroundResultInfluentialSelf-citationthe St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2014) · Nature Genetics · doi:10.1038/ng.2938 · Cited by 1,105
Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase
Kubicek, S., O'Sullivan, R. J., August, E. M., Hickey, E. R., Zhang, Q., Teodoro, M. L., Rea, S., Mechtler, K., Kowalski, J. A., Homon, C. A., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.017 · Cited by 859
Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
Behjati, S., Tarpey, P. S., Presneau, N., Scheipl, S., Pillay, N., Van Loo, P., Wedge, D. C., Cooke, S. L., Gundem, G., Davies, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2814 · Cited by 854
Bender, S., Tang, Y., Lindroth, A. M., Hovestadt, V., Jones, D. T. W., Kool, M., Zapatka, M., Northcott, P. A., Sturm, D., Wang, W., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.006 · Cited by 818
Tachibana, M., Sugimoto, K., Fukushima, T., & Shinkai, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101914200 · Cited by 784 · cited 1×
“G9a is an ∼120-kDa protein and contains an SET domain at its C terminus that catalyzes monoand dimethylation of histones at lysine 9 (11), and we previously showed that H3K9M peptides are capable of inhibiting activity of SUV39H1 and G9a, two H3K9-directed methyltransferases, in vitro (7).”
BackgroundCastel, D., Philippe, C., Calmon, R., Le Dret, L., Truffaux, N., Boddaert, N., Pagès, M., Taylor, K. R., Saulnier, P., Lacroix, L., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1478-0 · Cited by 664
Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2
Jiao, L., & Liu, X. (2015) · Science · doi:10.1126/science.aac4383 · Cited by 402 · cited 1×
“Indeed, a recent publication describing the first high-resolution X-ray crystal structure of PRC2 revealed that addition of the K27M peptide was necessary for crystallization (25).”
BackgroundG9a and Glp Methylate Lysine 373 in the Tumor Suppressor p53
Huang, J., Dorsey, J., Chuikov, S., Zhang, X., Jenuwein, T., Reinberg, D., & Berger, S. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.062588 · Cited by 383
Chen, M.-W., Hua, K.-T., Kao, H.-J., Chi, C.-C., Wei, L.-H., Johansson, G., Shiah, S.-G., Chen, P.-S., Jeng, Y.-M., Cheng, T.-Y., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0833 · Cited by 369
Protein lysine methyltransferase G9a acts on non-histone targets
Rathert, P., Dhayalan, A., Murakami, M., Zhang, X., Tamas, R., Jurkowska, R., Komatsu, Y., Shinkai, Y., Cheng, X., & Jeltsch, A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.88 · Cited by 347 · cited 1×
“Together with K9, arginine 8 (R8) on histone H3 peptides was reported to be necessary for both binding and catalysis by G9a (23).”
BackgroundStructural Biology of Human H3K9 Methyltransferases
Wu, H., Min, J., Lunin, V. V., Antoshenko, T., Dombrovski, L., Zeng, H., Allali-Hassani, A., Campagna-Slater, V., Vedadi, M., Arrowsmith, C. H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008570 · Cited by 268 · cited 1×
“These data are consistent with a proposed model where SAM facilitates folding of the G9a postSET domain, which forms part of the peptide binding site for H3K9 (18).”
ResultDiscovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a
Sweis, R. F., Pliushchev, M., Brown, P. J., Guo, J., Li, F., Maag, D., Petros, A. M., Soni, N. B., Tse, C., Vedadi, M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400496h · Cited by 193
Maksakova, I. A., Thompson, P. J., Goyal, P., Jones, S. J., Singh, P. B., Karimi, M. M., & Lorincz, M. C. (2013) · Epigenetics & Chromatin · doi:10.1186/1756-8935-6-15 · Cited by 188
( R )-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells
Barsyte-Lovejoy, D., Li, F., Oudhoff, M. J., Tatlock, J. H., Dong, A., Zeng, H., Wu, H., Freeman, S. A., Schapira, M., Senisterra, G. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407358111 · Cited by 185
Venneti, S., Santi, M., Felicella, M. M., Yarilin, D. A., Phillips, J. J., Sullivan, L. M., Martínez, D., Perry, A., Lewis, P. W., Thompson, C. B., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1338-3 · Cited by 156
Self-citationThe methyltransferase G9a regulates HoxA9-dependent transcription in AML
Lehnertz, B., Pabst, C., Su, L., Miller, M., Liu, F., Yi, L., Zhang, R., Krosl, J., Yung, E., Kirschner, J., et al. (2014) · Genes & Development · doi:10.1101/gad.236794.113 · Cited by 152
Béchet, D., Gielen, G. H., Korshunov, A., Pfister, S. M., Rousso, C., Faury, D., Fiset, P., Benlimame, N., Lewis, P. W., Lü, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1337-4 · Cited by 144
Self-citationLeung, D. C., Dong, K. B., Maksakova, I. A., Goyal, P., Appanah, R., Lee, S., Tachibana, M., Shinkai, Y., Lehnertz, B., Mager, D. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014660108 · Cited by 125
Brown, Z. Z., Müller, M. M., Jain, S. U., Allis, C. D., Lewis, P. W., & Muir, T. W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5060934 · Cited by 111
Self-citationG9a co-suppresses LINE1 elements in spermatogonia
Di Giacomo, M., Comazzetto, S., Sampath, S. C., Sampath, S. C., & O’Carroll, D. (2014) · Epigenetics & Chromatin · doi:10.1186/1756-8935-7-24 · Cited by 70
Poisoning the “histone code” in pediatric gliomagenesis
Lewis, P. W., & Allis, C. D. (2013) · Cell Cycle · doi:10.4161/cc.26356 · Cited by 30 · cited 1×
“oncohistones can achieve in tumor cell nuclei exceed the observed in vitro IC50 for these inhibitory peptides (5, 7, 26).”
BackgroundSelf-citationBrown, Z. Z., Müller, M. M., Kong, H. E., Lewis, P. W., & Muir, T. W. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500085 · Cited by 17
Self-citationLin, Y., Fan, H., Frederiksen, M., Zhao, K., Jiang, L., Wang, Z., Zhou, S., Guo, W., Gao, J., Li, S., et al. (2012) · Analytical Biochemistry · doi:10.1016/j.ab.2012.01.019 · Cited by 15
Brown, Z. Z., Müller, M. M., Kong, H. E., Lewis, P. W., & Muir, T. W. (2015) · Angewandte Chemie · doi:10.1002/ange.201500085 · Cited by 4
Self-citationBehjati, S., Tarpey, P. S., Presneau, N., Scheipl, S., Pillay, N., Loo, P. V., Wedge, D. C., Cooke, S. L., Gundem, G., Davies, H. R., et al. (2014) · Nature Genetics · doi:10.1038/ng0314-316 · Cited by 4
H3K9 組蛋白甲基轉移酶 G9a 促進癌症侵襲及轉移之探討
Chen, M., & 陳民瑋 (2010) · doi:10.6342/ntu.2010.01082
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature11026
Cited by
Yu, J.-R., Lee, C.-H., Oksuz, O., Stafford, J. M., & Reinberg, D. (2019) · Genes & Development · doi:10.1101/gad.325050.119 · Cited by 257
Mechanism of Cross-talk between H2B Ubiquitination and H3 Methylation by Dot1L
Worden, E. J., Hoffmann, N. A., Hicks, C. W., & Wolberger, C. (2019) · Cell · doi:10.1016/j.cell.2019.02.002 · Cited by 236
PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism
Jain, S. U., Do, T. J., Lund, P. J., Rashoff, A. Q., Diehl, K. L., Cieslik, M., Bajic, A., Juretic, N., Deshmukh, S., Venneti, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09981-6 · Cited by 208
Self-citationMultiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma
Stafford, J. M., Lee, C.-H., Voigt, P., Descostes, N., Saldaña-Meyer, R., Yu, J.-R., Leroy, G., Oksuz, O., Chapman, J. R., Suarez, F., et al. (2018) · Science Advances · doi:10.1126/sciadv.aau5935 · Cited by 191
Molecular architecture of polycomb repressive complexes
Chittock, E. C., Latwiel, S., Miller, T. C. R., & Müller, C. W. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160173 · Cited by 187
Metadata
- Authors
- Jayaram, H., Hoelper, D., Jain, S. U., Cantone, N., Lundgren, S. M., Poy, F., Allis, C. D., Cummings, R., Bellon, S., & Lewis, P. W.
- Affiliations
- Constellation Pharmaceuticals (United States) (US)
- University of Wisconsin–Madison (US)
- Rockefeller University (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2016-05-16
- Volume
- 113
- Issue
- 22
- Pages
- 6182-6187
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4896705
- OpenAlex
- W2403631776
- Cited by
- 92
- References
- 26
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 4 · 2023: 5 · 2022: 13 · 2021: 4 · 2020: 11 · 2019: 14 · 2018: 10 · 2017: 10 · 2016: 3
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- HHS | NIH | National Cancer Institute (P01CA196539)
- Starr Cancer Consortium (SCC I6-A614)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- S-adenosylmethionine, G9a, histone H3 lysine 9 methylation, oncohistones, SET domain methyltransferase, competitive inhibition, uncompetitive inhibition, ternary complex, co-crystal structure
- MeSH terms
- Histones, Humans, Lysine, Methionine, Mutation, Peptide Fragments, Histone-Lysine N-Methyltransferase, S-Adenosylmethionine, Substrate Specificity, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.